TVRD (Tvardi Therapeutics Inc.) stock: $0.96, $12.8M market cap, $15.8M cash, -$3.0M EV, $10.7M fully diluted market cap. Next expected readout: May-27. Lead program: TTI-101 (Hepatocellular Carcinoma), Phase 2. Data from Fully Diluted's biotech stocks database.
What they do
We are a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships Baylor College of Medicine: exclusive worldwide sublicenseable license to STAT3 inhibitor patents/technology (BCM First Agreement; Second Agreement for anaphylaxis terminated Apr 2026 as immaterial).
Indications
Hepatocellular carcinoma (HCC)(Phase 2)
Idiopathic pulmonary fibrosis (IPF)(Phase 2)
Catalysts
— Q4 2026
Status note First-generation direct STAT3 inhibitor in Phase 1b/2 (REVERT LIVER CANCER) in HCC. Phase 2 in IPF reported Oct 2025 did not meet its goals; company continues evaluating results for potential future development decisions.
TTI-109
Phase 1 · ActiveModality: oral small molecule (phosphate prodrug)
Target STAT3
Partnerships Baylor College of Medicine: exclusive worldwide sublicenseable license to STAT3 inhibitor patents/technology.
Indications
Ulcerative colitis (UC)(Stage not disclosed)
Status note Phosphate prodrug of TTI-101 designed for enhanced systemic delivery and tolerability. IND submitted Jun 2025; Phase 1 in healthy volunteers with topline data reported Jul 2026. UC selected as initial disease indication Jul 2026.
Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.